Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear pore complex-interacting protein family member B13 (NPIPB13) is a protein encoded by the NPIPB13 gene and classified as a member of the nuclear pore complex interacting protein family. The protein is predicted to be membrane-associated and has been annotated on the basis of sequence homology, but its exact cellular and molecular function remains uncharacterized in experimental literature[3][7]. There is no evidence that NPIPB13 participates directly in molecular transport, signaling, enzymatic activity, or other processes typical for therapeutic targets such as receptors, ion channels, or transporters. The gene has some genetic association with arthrogryposis multiplex congenita, but no causative or mechanistic data have been reported[3]. NPIPB13 is not listed as a therapeutic target and there are no known interacting drugs, biomarker roles, or safety concerns at this time. The most specific classification is a membrane protein of the nuclear pore complex-interacting protein family, but its biological and clinical relevance remains to be established.
None established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear pore complex-interacting protein family member B13 (NPIPB13).